- Home
- SAVA vs CET Comparison
SAVA vs CET Comparison
Compare SAVA & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- CET
- Stock Information
- Founded
- SAVA 1998
- CET 1929
- Country
- SAVA United States
- CET United States
- Employees
- SAVA N/A
- CET N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- CET Finance/Investors Services
- Sector
- SAVA Health Care
- CET Finance
- Exchange
- SAVA Nasdaq
- CET Nasdaq
- Market Cap
- SAVA 1.3B
- CET 1.3B
- IPO Year
- SAVA N/A
- CET N/A
- Fundamental
- Price
- SAVA $27.08
- CET $45.81
- Analyst Decision
- SAVA Buy
- CET
- Analyst Count
- SAVA 3
- CET 0
- Target Price
- SAVA $107.00
- CET N/A
- AVG Volume (30 Days)
- SAVA 1.9M
- CET 29.4K
- Earning Date
- SAVA 11-05-2024
- CET 01-01-0001
- Dividend Yield
- SAVA N/A
- CET 4.16%
- EPS Growth
- SAVA N/A
- CET 64.57
- EPS
- SAVA N/A
- CET 10.32
- Revenue
- SAVA N/A
- CET $23,374,777.00
- Revenue This Year
- SAVA N/A
- CET N/A
- Revenue Next Year
- SAVA N/A
- CET N/A
- P/E Ratio
- SAVA N/A
- CET $4.40
- Revenue Growth
- SAVA N/A
- CET 41.71
- 52 Week Low
- SAVA $8.79
- CET $34.58
- 52 Week High
- SAVA $42.20
- CET $46.20
- Technical
- Relative Strength Index (RSI)
- SAVA 46.80
- CET 60.93
- Support Level
- SAVA $26.10
- CET $45.28
- Resistance Level
- SAVA $31.65
- CET $46.12
- Average True Range (ATR)
- SAVA 2.55
- CET 0.35
- MACD
- SAVA -0.50
- CET -0.06
- Stochastic Oscillator
- SAVA 15.08
- CET 57.07
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.